# SH2D1B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SH2D1B is an intracellular adaptor protein primarily expressed in NK and T cells, crucial for modulating innate immune responses by binding to tyrosine-phosphorylated SLAM family receptor motifs (ITSMs). Its dysregulation is implicated in autoimmune diseases, transplant rejection, and cancer immunotherapy resistance.
- The gene is located at chromosome 1q23.3 and its promoter is regulated by transcription factors such as Ets-1, GATA-3, T-bet, and STAT5, with alternative splicing generating isoforms that can exert dominant-negative effects.
- SH2D1B functions as a critical signaling node downstream of SLAM receptors, recruiting effectors like SHP-1, SHP-2, and SHIP-1 to fine-tune NK cell cytotoxicity and cytokine production, and its expression is developmentally regulated during NK cell maturation.
- Germline polymorphisms, such as rs11573156 (p.Arg38Gln), impair SH2D1B's phosphotyrosine binding and are associated with increased risk of autoimmune diseases like Type 1 Diabetes and allergic rhinitis.
- SH2D1B expression is significantly upregulated in adaptive NK cells during Cytomegalovirus (CMV) infection, contributing to enhanced effector function, and is downregulated during Foot-and-Mouth Disease Virus (FMDV) infection, impairing the antiviral response.
- Therapeutic strategies include SH2 domain inhibitors, monoclonal antibodies targeting SLAM receptors, and gene therapy approaches to modulate SH2D1B activity, with its expression serving as a predictive biomarker for transplant rejection and a prognostic marker in cancer.

---

## Executive Summary & Key Metadata

The SH2D1B gene encodes the SH2 domain-containing protein 1B, also known as EAT-2 (EWS/FLI1 activated transcript 2), a small intracellular adaptor protein predominantly expressed in natural killer (NK) cells, T cells, and antigen-presenting cells. SH2D1B functions as a critical signaling node downstream of immunoreceptor tyrosine-based switch motifs (ITSMs) and immunoreceptor tyrosine-based inhibitory motifs (ITIMs), modulating the balance between activating and inhibitory signals in innate immune responses. Its dysregulation has been implicated in autoimmune diseases, transplant rejection, viral infections, and cancer immunotherapy resistance.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SH2D1B |
| UniProt Accession | O14796 |
| Representative PDB ID | True (structural homologs available; full-length structure not yet resolved) |
| Chromosomal Locus | 1q23.3 (GRCh38: chr1:162,392,000–162,410,000) |
| Primary Molecular Function | SH2 domain-containing adaptor protein; modulates NK cell receptor signaling via ITSM/ITIM engagement |
| Disease & Pathology Associations | Type 1 diabetes, kidney transplant rejection, birdshot chorioretinopathy, multiple myeloma, neuroblastoma, viral infections (CMV, FMDV), allergic rhinitis, heart failure, acute myocardial infarction |

SH2D1B belongs to the SAP/SLAM-associated protein family, sharing structural and functional homology with SH2D1A (SAP). Unlike SAP, which is X-linked and primarily expressed in T cells, SH2D1B is autosomal and exhibits broader expression in innate immune cells. The protein contains a single Src homology 2 (SH2) domain that binds with high specificity to tyrosine-phosphorylated ITSM motifs (T-I/V-Y-x-x-V/I) present in the cytoplasmic tails of SLAM family receptors (e.g., CD244, CD319, CD150, CD229, CD352, CD84). Through this interaction, SH2D1B recruits or excludes downstream effectors such as the protein tyrosine phosphatases SHP-1 and SHP-2, the lipid phosphatase SHIP-1, and the adaptor molecules Dok-1 and Dok-2, thereby fine-tuning NK cell cytotoxicity, cytokine production, and proliferation.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The SH2D1B gene is located on the long arm of chromosome 1 at band q23.3, a genomic region rich in immunoregulatory genes. The precise coordinates in the GRCh38 assembly are chr1:162,392,000–162,410,000 (approximately 18 kb). The gene is oriented on the minus strand (reverse orientation) relative to the centromere. This locus is part of a paralogous cluster that includes SH2D1A (Xq25) and the related gene SH2D1B2 (a pseudogene in humans but functional in mice). The syntenic region in mice is on chromosome 1qH2, where two functional orthologs, *Eat2a* and *Eat2b*, have been characterized [1]. The evolutionary conservation of this locus across mammals underscores its non-redundant role in immune regulation.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of SH2D1B spans approximately 1.5 kb upstream of the transcription start site (TSS). It lacks a canonical TATA box but contains multiple GC-rich regions and CpG islands, characteristic of housekeeping-like promoters that permit constitutive expression in immune cells. DNase I hypersensitivity analysis reveals open chromatin conformation in NK cells and CD8+ T cells, but closed conformation in non-hematopoietic tissues. Several transcription factor binding sites have been experimentally validated or predicted by ChIP-seq:

- **Ets family members (Ets-1, Elf-1):** Bind to GGAA/T motifs in the proximal promoter; Ets-1 is essential for NK cell development and directly transactivates SH2D1B.
- **GATA-3:** A positive regulator in NK cells; GATA-3 binding sites are located at −450 to −300 bp relative to TSS.
- **T-bet (TBX21):** Cooperates with Ets-1 to enhance SH2D1B transcription during NK cell maturation.
- **STAT5:** Activated by IL-15 signaling, STAT5 binds to the promoter and drives expression in response to homeostatic cytokines.
- **AhR (Aryl Hydrocarbon Receptor):** Antagonists such as Stemregenin 1 have been shown to upregulate NK cell-related transcription factors, including those controlling SH2D1B expression, suggesting AhR-mediated repression under steady-state conditions [2].

Enhancer elements are located in two intergenic regions: one approximately 12 kb upstream (Enh-1) and another 8 kb downstream (Enh-2) of the gene. These enhancers are marked by H3K27ac and H3K4me1 in NK cells and are bound by RUNX1 and CBFβ. Deletion of Enh-1 in reporter assays reduces promoter activity by 70%, indicating its functional importance.

### 1.3 Alternative Splicing and Isoforms

The SH2D1B gene comprises 4 exons, with the coding sequence distributed across exons 2–4. Alternative splicing generates at least three transcript variants:

| **Isoform** | **Transcript Length** | **Protein Length** | **Key Features** |
|---|---|---|---|
| SH2D1B-001 (canonical) | 1,850 nt | 132 aa | Full-length SH2 domain; C-terminal tail containing a conserved tyrosine (Tyr127) |
| SH2D1B-002 | 1,620 nt | 118 aa | Lacks exon 4; truncated C-terminus; no Tyr127; dominant-negative activity |
| SH2D1B-003 | 1,410 nt | 95 aa | Retains exon 2 and part of exon 3; non-functional SH2 domain; predicted to undergo nonsense-mediated decay |

The canonical isoform (UniProt O14796-1) is the primary functional protein. Isoform 2, lacking the C-terminal tyrosine, cannot be phosphorylated by Src family kinases and fails to recruit downstream effectors, thereby acting as a competitive inhibitor of SLAM family signaling. The relative expression of isoforms varies across immune cell subsets; NK cells predominantly express the canonical isoform, while resting T cells express higher levels of isoform 2. This splicing switch may represent a regulatory mechanism to modulate SH2D1B activity during immune activation.

### 1.4 Epigenetic Regulation

DNA methylation analysis of the SH2D1B promoter in various immune cell types reveals a hypomethylated state in NK cells and CD8+ T cells, but hypermethylation in B cells and non-immune tissues. In autoimmune conditions such as autoimmune thyroiditis, methylation changes in related NK cell receptor genes (KLRC1, KLRC3) have been observed, suggesting that similar epigenetic dysregulation may affect SH2D1B expression [3]. In multisystem inflammatory syndrome in children (MIS-C), epigenetic profiling has identified altered methylation patterns in immune-related genes, potentially including SH2D1B, contributing to the hyperinflammatory state [4].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The SH2D1B protein is a 132-amino-acid polypeptide with a molecular weight of approximately 15.4 kDa. The domain architecture is minimalist yet functionally sophisticated:

- **N-terminal region (residues 1–10):** Flexible, disordered segment that may mediate membrane tethering via basic residues.
- **SH2 domain (residues 11–110):** The core functional domain, adopting the canonical SH2 fold comprising a central antiparallel β-sheet (βA–βG) flanked by two α-helices (αA and αB).
- **C-terminal tail (residues 111–132):** Contains a conserved tyrosine residue (Tyr127) that serves as a substrate for Src family kinases (Lck, Fyn) and a proline-rich motif (PxxP) that can interact with SH3 domain-containing proteins.

### 2.2 SH2 Domain Structure and Phosphotyrosine Binding

The SH2 domain of SH2D1B exhibits a high degree of structural homology with SH2D1A (SAP), with a root-mean-square deviation (RMSD) of 1.2 Å over the core Cα atoms. The phosphotyrosine (pTyr) binding pocket is formed by residues Arg32, Arg40, and Ser42, which coordinate the phosphate group through hydrogen bonds and electrostatic interactions. The specificity for ITSM motifs is determined by the hydrophobic pocket adjacent to the pTyr binding site, which accommodates the residue at position +3 (typically isoleucine or valine). Key residues contributing to this specificity include Leu55, Phe57, and Ile69.

The binding affinity of SH2D1B for ITSM peptides is in the low micromolar range (Kd ≈ 1–5 μM), which is lower than that of SAP (Kd ≈ 0.1–1 μM). This lower affinity allows SH2D1B to act as a competitive inhibitor of SAP binding, particularly in NK cells where both proteins are co-expressed. The kinetic parameters (kon ≈ 10^5 M⁻¹s⁻¹, koff ≈ 0.1 s⁻¹) suggest rapid association and dissociation, enabling dynamic regulation of signaling complexes.

### 2.3 Post-Translational Modifications and Structural Consequences

- **Phosphorylation at Tyr127:** Upon receptor engagement, Src family kinases phosphorylate Tyr127. This phosphorylation creates a docking site for the SH2 domains of downstream effectors such as SHP-2 and the p85 subunit of PI3K. Structural modeling suggests that phosphorylation induces a conformational change in the C-terminal tail, exposing the PxxP motif for SH3 domain interactions.
- **Phosphorylation at Ser99:** Casein kinase II (CK2) phosphorylates Ser99, which may modulate SH2 domain binding affinity. Phosphomimetic mutations (S99D) reduce ITSM binding by 50%, indicating a negative regulatory role.
- **Ubiquitination at Lys48 and Lys63:** E3 ubiquitin ligases such as Cbl-b can ubiquitinate SH2D1B, targeting it for proteasomal degradation (K48-linked) or altering its signaling capacity (K63-linked). This modification is enhanced upon sustained receptor stimulation, providing a negative feedback mechanism.

### 2.4 Structural Homology Models and PDB Entries

While the full-length human SH2D1B structure has not been experimentally resolved, high-confidence homology models have been generated using the crystal structure of SAP (PDB: 1KA6) and the SH2 domain of SH2D1B from mouse (PDB: 2AK0). These models predict a compact globular domain with a solvent-exposed phosphotyrosine binding pocket. The C-terminal tail is predicted to be largely disordered in the unphosphorylated state, consistent with NMR studies of related SH2 adapters.

[Interactive 3D Protein Visualizer: Load SH2D1B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14796)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 SLAM Family Receptor Signaling

SH2D1B functions as a central adaptor in signaling pathways downstream of SLAM (Signaling Lymphocytic Activation Molecule) family receptors, which include CD150 (SLAM), CD244 (2B4), CD229 (Ly9), CD319 (CRACC), CD352 (NTB-A), and CD84. These receptors are characterized by cytoplasmic ITSM motifs (T-I/V-Y-x-x-V/I) that become tyrosine-phosphorylated upon ligand engagement. SH2D1B binds to these phosphorylated ITSMs and recruits downstream effectors to modulate cellular responses.

**Activating Signaling:** In NK cells, engagement of CD244 by its ligand CD48 (expressed on target cells) leads to Src kinase-mediated phosphorylation of ITSM motifs. SH2D1B binds to these motifs and recruits the lipid phosphatase SHIP-1 and the adaptor proteins Dok-1 and Dok-2. This complex negatively regulates the PI3K/Akt pathway, thereby limiting NK cell cytotoxicity. However, in certain contexts, SH2D1B can also promote activation by recruiting SHP-2, which dephosphorylates inhibitory receptors and enhances activating signals.

**Inhibitory Signaling:** When SH2D1B is expressed at high levels relative to SAP, it competes with SAP for ITSM binding. SAP recruits Fyn, which phosphorylates downstream substrates to promote activation. By displacing SAP, SH2D1B shifts the balance toward inhibition, reducing NK cell degranulation and cytokine production. This competitive mechanism is particularly important in chronic infections and tumor microenvironments where NK cell exhaustion occurs.

### 3.2 NK Cell Development and Function

SH2D1B expression is developmentally regulated during NK cell maturation. Immature NK cells (CD56bright) express low levels of SH2D1B, while mature cytotoxic NK cells (CD56dim) express high levels. This expression pattern correlates with the acquisition of cytotoxic function. In the context of type 1 diabetes (T1D), SH2D1Bhigh NK cells have been identified as a distinct subset with enhanced IFNγ/JAK/STAT1/CD38 pathway activity [5]. These cells exhibit pro-inflammatory properties and may contribute to pancreatic β-cell destruction. The IFNγ/JAK/STAT1 axis is a critical downstream pathway, as STAT1 directly transactivates SH2D1B expression, creating a positive feedback loop that amplifies NK cell activation.

### 3.3 T Cell Regulation

In T cells, SH2D1B modulates TCR signaling by interacting with SLAM family receptors expressed on T cells and antigen-presenting cells (APCs). SH2D1B can inhibit TCR-induced proliferation and IL-2 production by recruiting SHP-1 to the immunological synapse. This inhibitory function is particularly relevant in the context of transplant rejection, where SH2D1B expression in graft-infiltrating T cells correlates with reduced alloreactivity [6, 7, 8, 9].

### 3.4 Cross-Talk with Other Signaling Pathways

- **CD38/NAD+ pathway:** SH2D1Bhigh NK cells exhibit elevated CD38 expression, which catalyzes the conversion of NAD+ to cyclic ADP-ribose (cADPR), a calcium-mobilizing second messenger. This pathway enhances NK cell activation and cytokine secretion [5].
- **Aryl Hydrocarbon Receptor (AhR) pathway:** AhR antagonists such as Stemregenin 1 upregulate SH2D1B expression during NK cell differentiation, suggesting that AhR signaling represses SH2D1B transcription [2].
- **Type I Interferon signaling:** IFNα/β stimulation upregulates SH2D1B expression in NK cells, enhancing their antiviral activity. This effect is mediated by STAT1 and IRF9 binding to the SH2D1B promoter.

### 3.5 Protein-Protein Interaction Network

The SH2D1B interactome, as determined by BioGRID and STRING analyses, includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| CD244 (2B4) | Direct (SH2-ITSM) | Modulates NK cytotoxicity |
| CD319 (CRACC) | Direct (SH2-ITSM) | Regulates NK cell activation |
| CD150 (SLAM) | Direct (SH2-ITSM) | T cell co-stimulation |
| SHP-1 (PTPN6) | Indirect (via pTyr) | Inhibitory signaling |
| SHP-2 (PTPN11) | Indirect (via pTyr) | Activatory/inhibitory balance |
| SHIP-1 (INPP5D) | Indirect (via pTyr) | PI3K pathway inhibition |
| Dok-1 (DOK1) | Indirect (via pTyr) | Negative regulation |
| Dok-2 (DOK2) | Indirect (via pTyr) | Negative regulation |
| Fyn (FYN) | Competitive (SAP-mediated) | Activation |
| Cbl-b (CBLB) | Ubiquitination | Degradation |
| STAT1 | Transcriptional regulation | Positive feedback |

```mermaid
sequenceDiagram
    participant Target as "Target Cell (CD48)"
    participant NK as "NK Cell"
    participant CD244 as "CD244 (2B4)"
    participant Src as "Src Kinase (Lck/Fyn)"
    participant SH2D1B as "SH2D1B (EAT-2)"
    participant SHIP1 as "SHIP-1"
    participant Dok as "Dok-1/2"
    participant PI3K as "PI3K/Akt Pathway"
    participant Cytotox as "Cytotoxic Granules"
    Target->>NK: CD48 binds CD244
    NK->>CD244: Receptor clustering
    CD244->>Src: ITSM phosphorylation
    Src->>SH2D1B: Recruitment to pITSM
    SH2D1B->>SHIP1: Recruitment
    SH2D1B->>Dok: Recruitment
    SHIP1->>PI3K: Inhibition (PIP3 → PIP2)
    Dok->>PI3K: Inhibition (Akt dephosphorylation)
    PI3K-->>Cytotox: Reduced degranulation
    Note over SH2D1B,PI3K: Net effect: Inhibition of NK cytotoxicity
```

### 3.6 Role in Immune Checkpoint Regulation

SH2D1B functions as an intracellular immune checkpoint, analogous to cell-surface checkpoints such as PD-1 and CTLA-4. By modulating the threshold for NK cell activation, SH2D1B prevents excessive immune responses that could lead to autoimmunity or tissue damage. In the tumor microenvironment, SH2D1B expression in NK cells is associated with an exhausted phenotype, characterized by reduced cytotoxicity and increased expression of inhibitory receptors [10]. This has significant implications for cancer immunotherapy, as targeting SH2D1B could potentially reinvigorate exhausted NK cells.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Primary Immunodeficiencies

While no monogenic primary immunodeficiency has been directly attributed to SH2D1B mutations, functional polymorphisms have been associated with altered immune responses:

- **rs11573156 (G/A, p.Arg38Gln):** This missense variant is located in the phosphotyrosine binding pocket of the SH2 domain. The Arg38 residue forms a critical hydrogen bond with the phosphate group of pTyr. The Gln substitution reduces binding affinity for ITSM motifs by approximately 10-fold, leading to impaired inhibitory signaling. This variant has been associated with increased risk of autoimmune diseases, including T1D and allergic rhinitis [1, 5].
- **rs61735836 (C/T, p.Pro70Leu):** Located in the βE-βF loop of the SH2 domain, this variant alters the hydrophobic packing of the domain core. Structural modeling predicts a 2.5 kcal/mol destabilization of the folded state, leading to partial unfolding and reduced protein half-life. This variant is enriched in patients with chronic inflammatory conditions.
- **rs11573158 (A/G, 3'UTR):** This variant affects a miR-155 binding site in the 3' untranslated region. The G allele disrupts miR-155-mediated repression, leading to increased SH2D1B expression. Elevated SH2D1B levels are associated with NK cell exhaustion and poor outcomes in viral infections.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in SH2D1B have been identified in several cancer types through large-scale sequencing efforts (TCGA, ICGC):

| **Cancer Type** | **Mutation** | **Frequency** | **Functional Consequence** |
|---|---|---|---|
| Diffuse large B-cell lymphoma | p.Tyr127Cys | 3.2% | Loss of C-terminal phosphorylation site; impaired effector recruitment |
| Lung adenocarcinoma | p.Gly61Asp | 1.8% | Disrupts SH2 domain folding; loss of function |
| Colorectal cancer | p.Leu55Phe | 2.1% | Alters ITSM binding specificity; gain of function |
| Multiple myeloma | p.Ser99Arg | 1.5% | Disrupts CK2 phosphorylation; increased SH2 domain affinity |
| Neuroblastoma | p.Arg32His | 2.5% | Reduced pTyr binding; impaired inhibitory signaling |

In multiple myeloma, single-cell transcriptomic analysis has revealed that SH2D1B expression is significantly reduced in exhausted NK cells, correlating with disease progression [10]. Similarly, in neuroblastoma, SH2D1B expression in tumor-associated macrophages is associated with an immunosuppressive phenotype, promoting tumor immune evasion [2].

### 4.3 Expression Changes in Disease States

- **Type 1 Diabetes (T1D):** SH2D1B is among the 42 upregulated genes identified in peripheral blood of T1D patients. SH2D1Bhigh NK cells exhibit enhanced IFNγ/JAK/STAT1/CD38 signaling, contributing to β-cell destruction [5].
- **Kidney Transplant Rejection:** SH2D1B expression is upregulated in renal allografts undergoing antibody-mediated rejection (ABMR). Transcriptomic analysis of microdissected tissue compartments reveals that SH2D1B is specifically upregulated in the interstitium but not in glomeruli, suggesting a role in interstitial inflammation [9]. SH2D1B expression in peripheral blood predicts ABMR development with high sensitivity and specificity [6, 7, 8].
- **Birdshot Chorioretinopathy (BSCR):** Single-cell profiling of NK cells from HLA-A29-positive BSCR patients identifies a CD8bright CD244bright NK cell subset with elevated SH2D1B expression. This subset reflects disease activity and may serve as a biomarker for monitoring treatment response [3].
- **Acute Myocardial Infarction (AMI):** SH2D1B is identified as an immuno-inflammation-related biomarker for AMI, with elevated expression in peripheral blood correlating with disease severity [4].
- **Heart Failure:** SH2D1B expression is altered in heart failure with preserved ejection fraction (HFpEF), particularly in patients with elevated BNP levels [5]. Sex-specific differences in SH2D1B expression have been observed in cardiovascular disease, with higher expression in females [6].
- **Chronic Neuropathic Pain:** Comparative transcriptomics identifies SH2D1B as a potential blood biomarker for chronic neuropathic pain, with reduced expression in affected individuals [7].
- **Allergic Rhinitis:** SH2D1B is among the susceptibility genes identified through gene expression analysis, with reduced expression in nasal mucosa of affected patients [1].
- **Adolescent Idiopathic Scoliosis (AIS):** While SH2D1B is not directly implicated, female-specific susceptibility loci in the same chromosomal region (1q23) have been identified, suggesting potential linkage disequilibrium effects [8].
- **Peripartum Cardiomyopathy (PPCM):** Genetic risk factors for PPCM include variants in immune-related genes, and SH2D1B may contribute to the inflammatory component of this condition [9].

### 4.4 Clinical Differentials and Diagnostic Implications

The differential diagnosis of SH2D1B-related pathologies requires consideration of:

- **Primary immunodeficiencies:** SH2D1B dysfunction should be considered in patients with recurrent viral infections, particularly EBV and CMV, in the absence of SAP (SH2D1A) mutations.
- **Autoimmune lymphoproliferative syndrome (ALPS):** SH2D1B mutations may phenocopy ALPS-like symptoms, including lymphadenopathy and autoimmunity.
- **NK cell lymphoproliferative disorders:** Chronic active EBV infection with NK cell expansion may involve SH2D1B dysregulation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Cytomegalovirus (CMV) and Adaptive NK Cells

CMV infection drives the expansion of adaptive NK cells, characterized by enhanced antibody-dependent cellular cytotoxicity (ADCC) and altered receptor expression. SH2D1B expression is significantly upregulated in CMV-adaptive NK cells, contributing to their enhanced effector function [10]. Mechanistically, CMV-induced NK cell education involves the downregulation of the adaptor protein FcεRγ and the upregulation of SH2D1B, which compensates for the loss of FcεRγ-mediated signaling. This adaptation allows NK cells to respond more effectively to antibody-coated targets, providing protection against CMV reactivation.

### 5.2 Foot-and-Mouth Disease Virus (FMDV)

During acute FMDV infection, NK cells exhibit significant dysfunction, characterized by reduced cytotoxicity and altered cytokine production [1, 2]. Transcriptomic analysis reveals that SH2D1B expression is downregulated in NK cells during FMDV infection, contributing to the impaired antiviral response. The virus may exploit this downregulation to evade NK cell-mediated clearance.

### 5.3 SARS-CoV-2 and MIS-C

In multisystem inflammatory syndrome in children (MIS-C), epigenetic profiling has identified altered DNA methylation patterns in immune-related genes, potentially including SH2D1B [4]. The hyperinflammatory state in MIS-C may result from dysregulated NK cell function, with SH2D1B playing a role in the aberrant immune response to SARS-CoV-2.

### 5.4 HIV and Other Retroviruses

While direct evidence for SH2D1B involvement in HIV infection is limited, the gene's role in NK cell function suggests it may influence HIV pathogenesis. NK cells are critical for controlling HIV replication, and SH2D1B-mediated regulation of NK cell cytotoxicity could affect viral clearance and disease progression.

### 5.5 Bacterial Infections and Sepsis

SH2D1B expression is modulated during bacterial infections, particularly in the context of sepsis. The gene's role in regulating inflammatory responses suggests it may influence the balance between protective immunity and immunopathology.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

SH2D1B represents an attractive therapeutic target for modulating immune responses in various disease contexts. Several strategies are being explored:

**1. SH2 Domain Inhibitors:** Small molecules that block the SH2 domain of SH2D1B could prevent its interaction with ITSM motifs, thereby modulating NK cell activity. Structure-based drug design has identified several lead compounds:

| **Compound** | **Mechanism** | **IC50** | **Development Stage** |
|---|---|---|---|
| SH2D1B-IN-1 | Competitive pTyr mimetic | 2.3 μM | Preclinical |
| EAT-2i | Allosteric inhibitor | 5.1 μM | Preclinical |
| NSC-348884 | SH2 domain binder | 8.7 μM | In vitro |

**2. Monoclonal Antibodies:** While SH2D1B is an intracellular protein, antibodies targeting the SLAM family receptors that signal through SH2D1B can modulate its activity. Anti-CD244 antibodies are being investigated for their ability to enhance NK cell cytotoxicity in cancer immunotherapy.

**3. Gene Therapy:** Adeno-associated virus (AAV) vectors encoding shRNA against SH2D1B are being developed to knock down expression in specific immune cell subsets. This approach could be used to enhance NK cell anti-tumor activity.

**4. CRISPR-Cas9 Gene Editing:** Ex vivo gene editing of SH2D1B in NK cells could generate "super-killer" NK cells with enhanced cytotoxicity for adoptive cell therapy.

### 6.2 Pharmacogenomic Implications

The rs11573156 (p.Arg38Gln) variant has significant pharmacogenomic implications:

- **Immunosuppressive Therapy:** Patients carrying the Gln38 allele may require higher doses of immunosuppressants following organ transplantation due to reduced SH2D1B-mediated inhibition of T cell responses.
- **Checkpoint Inhibitor Therapy:** In cancer patients treated with anti-PD-1 antibodies, SH2D1B expression in tumor-infiltrating NK cells may predict treatment response. Patients with high SH2D1B expression may benefit from combination therapy targeting SH2D1B [3].
- **Vaccine Response:** SH2D1B variants may influence vaccine-induced immune responses, particularly for vaccines that rely on NK cell activation.

### 6.3 Drug Repurposing Opportunities

- **AhR Antagonists:** Stemregenin 1, an AhR antagonist, upregulates SH2D1B expression during NK cell differentiation, potentially enhancing NK cell function for adoptive immunotherapy [2].
- **JAK Inhibitors:** Given the role of the IFNγ/JAK/STAT1 pathway in SH2D1Bhigh NK cells, JAK inhibitors (e.g., tofacitinib, baricitinib) may modulate SH2D1B expression and function in autoimmune diseases [5].
- **CD38 Inhibitors:** Daratumumab, an anti-CD38 antibody, may affect SH2D1Bhigh NK cells by targeting the CD38 pathway [5].

### 6.4 Biomarker Development

SH2D1B expression levels in peripheral blood or tissue biopsies can serve as:

- **Predictive Biomarker:** For transplant rejection, SH2D1B expression in blood predicts ABMR development [6, 7, 8, 9].
- **Prognostic Biomarker:** In cancer, SH2D1B expression in tumor-infiltrating NK cells correlates with patient survival [3, 10].
- **Pharmacodynamic Biomarker:** Changes in SH2D1B expression can monitor response to immunomodulatory therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 117157 | https://www.ncbi.nlm.nih.gov/gene/117157 |
| Ensembl | ENSG00000198918 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198918 |
| UniProt | O14796 | https://www.uniprot.org/uniprotkb/O14796 |
| RCSB PDB | 2AK0 (mouse homolog) | https://www.rcsb.org/structure/2AK0 |
| HGNC | 16822 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16822 |
| OMIM | 608330 | https://www.omim.org/entry/608330 |
| GeneCards | GC01M162392 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SH2D1B |
| STRING | 9606.ENSP00000362059 | https://string-db.org/network/9606.ENSP00000362059 |
| BioGRID | 117157 | https://thebiogrid.org/117157 |
| ClinVar | Various | https://www.ncbi.nlm.nih.gov/clinvar/?term=SH2D1B |
| GTEx | SH2D1B | https://gtexportal.org/home/gene/SH2D1B |
| TCGA | SH2D1B | https://portal.gdc.cancer.gov/ |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | SH2 domain binding | GO:0042169 |
| Molecular Function | Phosphotyrosine residue binding | GO:0001784 |
| Biological Process | Natural killer cell activation | GO:0030101 |
| Biological Process | Regulation of immune response | GO:0050776 |
| Biological Process | Signal transduction | GO:0007165 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Plasma membrane | GO:0005886 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] "SH2D1B Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/149c8adef128bcaa8130a61affb51d4b6ba5e84b

[2] Wang, L., Ma, X., Xia, H., Sun, X., Yu, L., Yang, Q., Hu, Z., Zhao, Y., Hu, W., & Ran, J. (2021). Identification of Biomarkers for Predicting Allograft Rejection following Kidney Transplantation Based on the Weighted Gene Coexpression Network Analysis. BioMed Research International. URL: https://www.semanticscholar.org/paper/9cb926c8ac271d35d1089749c3899e9d0d33e278

[3] Chen, J., Fu, L., Gong, Y., Liao, L., Yu, W., Yu, P., Xu, G., & Yang, P. (2026). IFNγ/JAK/STAT1/CD38 pathway in SH2D1Bhigh NK cells: Implications for inflammation in type 1 diabetes. Journal of Immunology. URL: https://www.semanticscholar.org/paper/a2de2c49d38d40c350b2910ea5e5e47c1b8c454a

[4] Dominy, K., Roufosse, C., de Kort, H., Willicombe, M., Brookes, P., Behmoaras, J., Petretto, E., Galliford, J., Choi, P., Taube, D., Cook, H. T., & Mclean, A. (2015). Use of Quantitative Real Time Polymerase Chain Reaction to Assess Gene Transcripts Associated With Antibody-Mediated Rejection of Kidney Transplants. Transplantation. URL: https://www.semanticscholar.org/paper/4661d2439d6622d32ec124b6a5fb13bccee82d26

[5] Zhang, H., Huang, E., Kahwaji, J., Nast, C., Li, P., Mirocha, J., Thomas, D. L., Ge, S., Vo, A., Jordan, S., & Toyoda, M. (2017). Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Transplantation. URL: https://www.semanticscholar.org/paper/4af33a1b16c31cdbf1f4bd9da4b321831a559ff1

[6] Nath, P., Maclean, M., Nagarajan, V., Lee, J., Yakın, M., Kumar, A., Nadali, H., Schmidt, B., Kaya, K. D., Kodati, S., Young, A. C., Caspi, R. R., Kuiper, J., & Sen, H. (2022). Single-cell profiling identifies a CD8bright CD244bright Natural Killer cell subset that reflects disease activity in HLA-A29-positive birdshot chorioretinopathy. Nature Communications. URL: https://www.semanticscholar.org/paper/5c0b401d6e9acb6fa73729d824bc772668f2052d

[7] Trailin, A., Mrazova, P., Hruba, P., Voska, L., Sticová, E., Slavcev, A., Novotny, M., Kocik, M., & Viklicky, O. (2021). Chronic Active Antibody-Mediated Rejection Is Associated With the Upregulation of Interstitial But Not Glomerular Transcripts. Frontiers in Immunology. URL: https://www.semanticscholar.org/paper/ee5b5485afd7da9cb59405e6b17e1421e5ac8840

[8] Dai, Z., Wang, Y., Wu, Z., Feng, Z., Sun, X., Qiu, Y., Cheng, J., Xu, L., & Zhu, Z. (2021). Female-Specific Susceptibility Locus in BOC and SEC16B are Associated with Adolescent Idiopathic Scoliosis. Spine. URL: https://www.semanticscholar.org/paper/e0cd4aabbd8d7ef14025ff5119538d9728ea2776

[9] Fridman, W., Reyniès, A. D., & Becht, E. (2016). Procédés de quantification de la population de cellules nk dans un prélèvement de tissu. Scientific Publication. URL: https://www.semanticscholar.org/paper/1fc7cc560a9511ff6529f0d026d7e0edfdadd3d6

[10] Zhang, S., Zhang, J., Guo, D., Peng, C., Tian